Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Association for Cancer Research (AACR)
Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Authored Items
Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
By
Mark A. Socinski, MD
Dual IO 2021 - Year in Review
Dual IO 2021 - Year in Review
Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma.
Read More ›
Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC
By
Mark A. Socinski, MD
Dual IO 2021 - Year in Review
Dual IO 2021 - Year in Review
Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC.
Read More ›
Key Abstracts from ASCO 2021 in NSCLC
By
Mark A. Socinski, MD
American Society of Clinical Oncology (ASCO)
AACR & ASCO 2021 – Midyear Review
Dr Mark Socinski reviews a broad variety of studies, including the evolving role of
EGFR
inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC.
Read More ›
Practice-Changing Data in NSCLC from ASCO 2021
By
Mark A. Socinski, MD
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Dr Mark Socinski provides his insights into important new data on
EGFR
inhibitors and immunotherapy in the first-line setting for NSCLC.
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us